CMHC Chicago Conference Guide 2019 by Tarsus Medical

Welcome to the 14th Annual Cardiometabolic Health Congress in our new location: Chicago! It is an exciting and stimulating time to be involved in the field of cardiometabolic health, as we continuously experience newly developed and introduced therapies, novel treatments, and inventive approaches: all of which collectively provide enhanced care and better patient outcomes. CMHC continues to confront and tackle the enormous clinical and economic challenges that cardiometabolic disease presents, providing dynamic and interactive educational opportunities surrounding the latest clinical research in the landscape of cardiometabolic care. CMHC is committed to spearheading, developing, and hosting the most clinically relevant conferences in cardiometabolic health—and bringing together a community of clinicians: all of whom have a vested interest in remaining at the intersection of science and medicine. This year’s meeting will run from Thursday to Sunday, and has been carefully curated to provide our attendees with the optimal educational experience, as we continue to improve both our educational methods & strategies, and ability to address the prevention, diagnosis, and management of cardiometabolic disease. This year’s pre-conference will be hosted in collaboration with MedTech Impact on Wellness: a content & event-based brand that explores the landscape of digital health. Given the rapid progression of medical technology and its integration into patient care, the partnership between CMHC and MedTech represents a strong commitment to improving diagnosis and treatment through innovation and evolution. Pre-conference sessions include An Introduction to Big Data and Its Role in Cardiometabolic Health, New Generation Engagement: The New Frontier, as well as sessions on genetic testing in cardiometabolic medicine, clinical uses of diabetic devices, and other digital health technology to incorporate into everyday management. Friday will feature the popular session FDA Update and Late Breaking Clinical Trials, in addition to keynote presenter Daniel D. Drucker, MD who will discuss the GLP-1 agonists: investigating the pleiotropic effects for cardio renal protection; What are the potential mechanisms involved?. The fully packed agenda continues with stimulating sessions on both Friday and Saturday, including Lifestyle Interventions for Prevention 2 www.cardiometabolichealth.org

of Diabetes and the Metabolic Syndrome. Finally, we will close on Sunday with the increasingly popular Obesity and Lifestyle Management track featuring NASH in a Dash. In addition to the extensive agenda, the conference will provide supplemental educational opportunities, with certified satellite symposia and professional medical education sessions. These highly anticipated sessions have collectively been developed through the latest educational innovations, designed to enhance your learning experience through the utilization of infographics, iPads, animated videos, and simulations. The complimentary Small Group Workshops are back again, aiming to provide you with a more intimate learning atmosphere and enhanced educational experience. The eight workshops will focus on attendeerequested topics such as insulin access, biomarkers in CVD, statin intolerance, CV risk reduction management, obesity pharmacotherapy, BP monitoring, and hyperkalemia. Not only is our agenda engineered to deliver the most current innovations and breakthroughs in science, but we have also updated our Exhibit Hall—and increased our socializing & networking opportunities throughout the conference. Both the Poster Presentations and Passport to Prizes are back by popular demand, and our new Tell Us Your Why showcase features an area dedicated to sharing each attendee’s rationale for attending CMHC, so that we can come together collectively and have a dialogue on the increasing importance of cardiometabolic health education. On behalf of the entire CMHC team, we want to thank each of you for bringing your vision, expertise, and commitment to our event. As the leaders of the cardiometabolic field, you have the knowledge, motivation, and experience to help us pave the future of health—and are truly our greatest asset. We hope you enjoy your stay in Chicago and appreciate your continued dedication and support.

CHAIRPERSONS CHRISTIE M. BALLANTYNE, MD Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

GEORGE L. BAKRIS, MD Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

ROBERT H. ECKEL, MD Professor of Medicine, Emeritus Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics, Emeritus Charles A. Boettcher II Chair in Atherosclerosis University of Colorado Anschutz Medical Campus Aurora, CO

JAY S. SKYLER, MD Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

TABLE OF CONTENTS Welcome Letter

2-3

Hours of Operation

Meet the Experts

Schedule-at-a-Glance

7 - 12

Expert Speaker Line-Up

13 - 16

Association & Media Partners

Exhibitor Index

Exhibitor Listings

21 - 24

Professional Medical Education (Non-CME) 26 - 27 14th Annual CMHC Accreditation

28 -29

CME Symposia

32 - 45

Scientific Poster Sessions

46 - 48

www.cardiometabolichealth.org

HOURS OF OPERATION REGISTRATION HOURS Thursday, October 10 9:30 AM - 6:30 PM Friday, October 11 6:00 AM - 6:00 PM Saturday, October 12 6:00 AM - 6:00 PM Sunday, October 13 7:00 AM - 12:00 PM 0

6:0

7:0

8:0

9:0

:00 10

:00 11

:00 12

1:0

2:0

3:0

4:0

5:0

6:0

:00 12

1:0

2:0

3:0

4:0

5:0

6:0

EXHIBIT BREAK HOURS Friday, October 11 Saturday, October 12 :00 10

:00 11

FRIDAY, OCTOBER 11

SATURDAY, OCTOBER 12

Morning Break

10:15 am – 11:15 am

Morning Break

10:00 am – 11:00 am

Afternoon Break

2:25 pm – 3:25 pm

Afternoon Break

2:15 pm – 3:15 pm

Welcome Reception

5:25 pm – 6:25 pm

Happy Hour

5:20 pm – 6:20 pm

5:25 PM - 6:25 PM

Grand Horizon ABC (Level 4)

4 www.cardiometabolichealth.org

MEET THE EXPERTS

LOCATED IN GRAND HORIZON ABC

FRIDAY, OCTOBER 11

SATURDAY, OCTOBER 12

MORNING BREAK 10:15 am – 11:15 am

MORNING BREAK 10:00 am – 11:00 am

•

Christie M. Ballantyne, MD

•

Christie M. Ballantyne, MD

•

Deepak L. Bhatt, MD, MPH

•

Kim K. Birtcher, PharmD

•

Robert H. Eckel, MD

•

Roger S. Blumenthal, MD

•

Keith C. Ferdinand, MD

•

Amit V. Khera, MD

•

Edward S. Horton, MD

•

Margo B. Minissian, PhD, ACNP, FAHA, FNLA

•

Jay S. Skyler, MD

•

Patrick M. Moriarty, MD, FACC, FACP

AFTERNOON BREAK 2:25 pm – 3:25 pm

AFTERNOON BREAK 2:15 pm – 3:15 pm

•

George L. Bakris, MD

•

George L. Bakris, MD

•

Lawrence Blonde, MD

•

Biykem Bozkurt, MD, PhD, FACC, FAHA

•

Robert H. Eckel, MD

•

Javed Butler, MD, MPH, MBA

•

Julio Rosenstock, MD

•

Mariell Jessup, MD

•

Jay S. Skyler, MD

•

Andy Y. Lee, MD

•

Virginia Valentine, APRN-CNS,

•

Peter A. McCullough, MD, MPH

BC-ADM, CDE, FAADE

•

Alanna A. Morris MD, MSc, FHFSA, FACC

•

Tracy Y. Wang, MD

•

Gurusher S. Panjrath, MD, FACC, FAHA

•

Aldo Peixoto, MD

•

Ileana L. Piña, MD, MPH

•

Raymond R. Townsend, MD

•

Michael A. Weber, MD

www.cardiometabolichealth.org

SCHEDULE AT A GLANCE THURSDAY OCTOBER 10, 2019 PRE-CONFERENCE CARDIOMETABOLIC TECH SUMMIT HOSTED IN COLLABORATION WITH MEDTECH IMPACT 11:00 AM - 11:10 AM Great Lakes AB 11:10 AM - 11:30 AM Great Lakes AB 11:30 AM - 11:50 AM Great Lakes AB 12:05 PM - 1:05 PM Great Lakes AB 1:20 PM - 2:05 PM Great Lakes AB 2:05 PM - 2:15 PM Great Lakes AB 2:15 PM - 2:25 PM Great Lakes Foyer 2:25 PM - 2:40 PM Great Lakes AB 2:40 PM - 3:10 PM Great Lakes AB 3:10 PM - 3:40 PM Great Lakes AB 3:40 PM - 4:00 PM Great Lakes AB 4:00 PM - 4:15 PM Great Lakes Foyer 4:15 PM - 5:15 PM Great Lakes AB 5:20 PM - 6:20 PM Great Lakes AB 6:30 PM - 7:30 PM Great Lakes AB

Opening Remarks Chair: Anne L. Peters, MD An Introduction to Big Data and Its Role in Cardiometabolic Health Eric D. Peterson, MD When is Genetic Testing Useful in Cardiometabolic Medicine Elizabeth M. McNally, MD, PhD PME Lunch Symposium (Non-CME) Reviewing A1C and Cardiovascular Safety Data in T2D Therapies Sponsored by Novo Nordisk. Joshua M. Stolker, MD Real-World Evidence in Cardiometabolic Health Lawrence Blonde, MD Expert Panel Discussion and Q & A Chair: Anne L. Peters, MD Panelists: Lawrence Blonde, MD; Elizabeth M. McNally, MD, PhD; Eric D. Peterson, MD Mini-break New Generation Engagement: The New Frontier Patrick Wayte Moving Beyond A1C: Diabetes Devices and Their Clinical Use Anne L. Peters, MD Wearables and Digital Health in Arrhythmia Management: Where Are We Headed? Mintu Turakhia, MD Expert Panel Discussion and Q & A Chair: Anne L. Peters, MD Panelists: Mintu Turakhia, MD; Patrick Wayte Mini-break PME Light Bites Symposium (Non-CME) Cardiovascular Patient Cases Sponsored by Amgen, Inc. Eliot A. Brinton, MD PME Light Bites Symposium (Non-CME) Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study Sponsored by Amarin Pharma Inc. George Grunberger, MD PME Dinner Symposium (Non-CME) JardianceÂ® (empagliflozin) tablets: Data from the comprehensive clinical development program Sponsored by Boehringer-Ingelheim. Jonathan D. Rich, MD, FACC, FHFSA

www.cardiometabolichealth.org

SMALL GROUP WORKSHOPS *Pre-registration is required

SCHEDULE AT A GLANCE FRIDAY OCTOBER 11, 2019 SESSION I - DIABETES 6:30 AM - 7:45 AM Great Lakes AB 7:55 AM - 8:00 AM Grand Horizon DEFG 8:00 AM - 9:30 AM Grand Horizon DEFG 9:30 AM - 10:15 AM Grand Horizon DEFG 10:15 AM - 11:15 AM Grand Horizon ABC

CME Breakfast Symposium A Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc. Chair: George L. Bakris, MD Faculty: Rajiv Agarwal, MD; Ileana L. PiÃ±a, MD, MPH Opening Remarks Christie M. Ballantyne, MD FDA Update and Late Breaking Trials Christie M. Ballantyne, MD; Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Jay S. Skyler, MD Keynote GLP-1 agonists: investigating the pleiotropic effects for cardio renal protection; What are the potential mechanisms involved? Daniel J. Drucker, MD Morning Break & Exhibits

8 www.cardiometabolichealth.org

10:20 AM - 11:10 AM WORKSHOP 1 Great Lakes B ACC and ADA Unified Approach to CV Risk Reduction Pre-Registration Required 11:15 AM - 12:05 PM Lifestyle Interventions for Prevention of Diabetes and the Metabolic Syndrome Grand Horizon DEFG Edward S. Horton, MD 12:20 PM - 1:35 PM CME Lunch Symposium A Great Lakes AB Reducing Cardiovascular Risk: A Paradigm Shift in T2DM Management Supported by an educational grant from Novo Nordisk. Chair: Robert H. Eckel, MD Faculty: Lawrence Blonde, MD; Tracy Y. Wang, MD 12:20 PM - 1:35 PM CME Lunch Symposium B Great Lakes EF TBA 1:45 PM - 2:25 PM Navigating Insulin Management in Patients with T2DM Grand Horizon DEFG Irl B. Hirsch, MD 2:25 PM - 3:25 PM Afternoon Break & Exhibits Grand Horizon ABC 2:30 PM - 3:15 PM WORKSHOP 2 Great Lakes B Navigating Insulin Access and Cost Pre-Registration Required Irl B. Hirsch, MD 3:25 PM - 4:05 PM What to Choose? Initial Combination Therapy versus Sequential Therapy Grand Horizon DEFG Julio Rosenstock, MD 3:25 PM - 4:05 PM WORKSHOP 3 Great Lakes B Progresses and Challenges in Obesity Pharmacotherapy Pre-Registration Required W. Timothy Garvey, MD 4:05 PM - 5:20 PM Multidisciplinary Case Consults in Diabetes Management Grand Horizon DEFG Chair: Jay S. Skyler, MD Panelists: George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; Irl B. Hirsch, MD; Julio Rosenstock, MD; Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE 4:10 PM - 5:00 PM WORKSHOP 4 Great Lakes B Navigating the Prior Authorization Process Pre-Registration Required Kim K. Birtcher, PharmD

Sponsored by Ackea Therapeutics.

Opening Remarks George L. Bakris, MD Hypertension: Integrating the Guidelines and Addressing the Gaps Chair: George L. Bakris, MD Panelists: Aldo Peixoto, MD; Raymond R. Townsend, MD; Michael A. Weber, MD Afternoon Break & Exhibits WORKSHOP 7 When Do You Use Ambulatory BP Monitoring? Pre-Registration Required Raymond R. Townsend, MD SGLT2 Inhibitors and Renal Preservation George L. Bakris, MD Role of Metabolic Syndrome in HFpEF Mariell Jessup, MD Updates in HF and T2DM Javed Butler, MD, MPH, MBA WORKSHOP 8 The Role of Potassium-Binding Agents in Optimizing HF Guidelines Pre-Registration Required Ileana L. PiÃ±a, MD, MPH Closing Remarks George L. Bakris, MD

Passport to Prizes winners will be announced.

6:30 PM - 7:15 PM PME Light Bites Symposium (Non-CME) Great Lakes EF Understanding CKD in T2D: The Risks, Recognition, and Clinical Management Sponsored by Bayer. Peter A. McCullough, MD, MPH; Luiza Caramori, MD 7:20 PM - 8:35 PM CME Dinner Symposium Great Lakes AB Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes Multi-supported by educational grants from Sanofi and Esperion. Chair: Christie M. Ballantyne, MD Faculty: Leslie Cho, MD

www.cardiometabolichealth.org

SCHEDULE AT A GLANCE SUNDAY, OCTOBER 13, 2019 SESSION IV - OBESITY/LIFESTYLE 7:15 AM - 7:50 AM Breakfast Grand Horizon EFG 7:55 AM - 8:00 AM Opening Remarks Grand Horizon EFG Robert H. Eckel, MD 8:00 AM - 8:45 AM Nutrition Beats Attrition: The Low Hanging Fruit for Cardiometabolic Health Grand Horizon EFG Stephen Devries, MD 8:45 AM - 9:15 AM Updates on Leptin and Obesity Grand Horizon EFG Martin Myers, MD, PhD 9:15 AM - 9:45 AM Mechanism for Benefit of Metabolic Surgery Grand Horizon EFG Lee M. Kaplan, MD, PhD 9:45 AM - 10:15 AM Lifestyle Approaches to Weight Reduction - Challenges Before Us Grand Horizon EFG Holly R. Wyatt, MD 10:15 AM - 10:25 AM Mini-break Grand Horizon Foyer 10:25 AM - 11:05 AM Mechanisms of Obesity and Hypertension Grand Horizon EFG George L. Bakris, MD John E. Hall, PhD 11:05 AM - 11:45 AM NASH in a Dash Grand Horizon EFG Christos S. Mantzoros, MD, DSc 11:45 AM - 12:45 PM Multidisciplinary Case Consults in Obesity/Lifestyle Grand Horizon EFG Chair: Robert H. Eckel, MD Panelists: George L. Bakris, MD; Shannon Christen, RD, CDE; Holly R. Wyatt, MD 12:45 PM - 12:50 PM Closing Remarks Grand Horizon EFG Robert H. Eckel, MD

Pre-registration is not required for satellite symposia or PMEs

12 www.cardiometabolichealth.org

EXPERT SPEAKER LINE-UP CHAIRPERSONS George L. Bakris, MD

Christie M. Ballantyne, MD

Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

Robert H. Eckel, MD

Jay S. Skyler, MD

Professor of Medicine, Emeritus Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics, Emeritus Charles A. Boettcher II Chair in Atherosclerosis University of Colorado Anschutz Medical Campus Aurora, CO

Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

SENIOR PLANNING COMMITTEE Deepak L. Bhatt, MD, MPH

Pamela B. Morris, MD

Professor of Medicine Harvard Medical School Executive Director Interventional Cardiovascular Programs Brigham and Womenâ&#x20AC;&#x2122;s Hospital Heart and Vascular Center Boston, MA

Director, Seinsheimer Cardiovascular Health Program Co-Director, Womenâ&#x20AC;&#x2122;s Heart Care Medical University of South Carolina Charleston, SC

Keith C. Ferdinand, MD, FACC, FAHA

Clyde W. Yancy, MD, MSc, MACP

Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Div. of Cardiology, Northwestern Univ. Feinberg School of Medicine Assoc. Director, Bluhm Cardiovascular Institute Northwestern Memorial Hospital Chicago, IL

www.cardiometabolichealth.org

DISTINGUISHED FACULTY Rajiv Agarwal, MD

Kim K. Birtcher, PharmD

Professor of Medicine Indiana University School of Medicine & VA Medical Center Indianapolis, IN

Clinical Professor University of Houston College of Pharmacy Houston, TX

Lawrence Blonde, MD

Roger S. Blumenthal, MD

Director, Ochsner Diabetes Clinical Research Unit Frank Riddick Diabetes Institute Department of Endocrinology Ochsner Medical Center New Orleans, LA

The Kenneth Jay Pollin Professor of Cardiology Director The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Baltimore, MD

Biykem Bozkurt, MD, PhD, FACC, FAHA

Eliot A. Brinton, MD*

The Mary and Gordon Cain and W.A. “Tex” and Deborah Moncrief, Jr., Chair Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center Director, Winters Center for Heart Failure Research Associate Director, Cardiovascular Research Institute Baylor College of Medicine Houston, TX

Director, Atherometabolic Research Utah Foundation for Biomedical Research Salt Lake City, UT

Javed Butler, MD, MPH, MBA

Luiza Caramori, MD, PhD, MSc*

Professor and Chairman, Department of Medicine University of Mississippi Jackson, MS

Associate Professor of Medicine Division of Diabetes, Endocrinology and Metabolism Department of Medicine at the University of Minnesota Minneapolis, MN

Leslie Cho, MD

Shannon Christen, RD, CDE

Professor of Medicine Section Head, Preventive Cardiology and Rehabilitation Cleveland Clinic Cleveland, OH

Registered Dietitian Certified Diabetes Educator Division of Endocrinology, Metabolism & Diabetes Division of Cardiology – Cardiac & Vascular Prevention Program PCSK9 Coordinator at UCHealth University of Colorado Hospital Anschutz Medical Campus Aurora, CO

Stephen Devries, MD, FACC

Daniel J. Drucker, MD

Executive Director Gaples Institute for Integrative Cardiology Deerfield, IL

Professor of Medicine Lunenfeld Tanenbaum Research Institute Mt. Sinai Hospital University of Toronto Toronto, Ontario, Canada

W. Timothy Garvey, MD

George Grunberger, MD*

Butterworth Professor Director, Diabetes Research Center University of Alabama at Birmingham Birmingham, AL

Chairman Grunberger Diabetes Institute Bloomfield Hills, MI

John E. Hall, PhD

Irl B. Hirsch, MD

Arthur C. Guyton Professor and Chair Department of Physiology and Biophysics Director, Mississippi Center for Obesity Research University of Mississippi Medical Center Jackson, MS

Professor of Medicine Diabetes Treatment and Teaching Chair University of Washington Medical Center Medical Director UWMC Diabetes Care Center Seattle, WA

14 www.cardiometabolichealth.org

Edward S. Horton, MD

Mariell Jessup, MD

Professor of Medicine, Harvard Medical School Senior Investigator, Joslin Diabetes Center Boston, MA

Chief Science and Medical Officer American Heart Association Dallas, TX

Lee M. Kaplan, MD, PhD

Amit Khera, MD, MSc

Associate Professor of Medicine Harvard Medical School Director, Obesity, Metabolism & Nutrition Institute Massachusetts General Hospital Boston, MA

Associate Director, Precision Medicine Unit, Center for Genomic Medicine, MGH Associate Director, Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard Instructor of Medicine, Harvard Medical School Cardiologist, Corrigan Minehan Heart Center, MGH Massachusetts General Hospital Boston, MA

Andy Y. Lee, MD

Christos S. Mantzoros, MD, DSc

Fellow, Advanced Heart Failure and Transplant University of Washington Seattle, WA

Professor of Medicine Harvard Medical School Boston, MA

Peter A. McCullough, MD, MPH**

Elizabeth M. McNally, MD, PhD

Professor of Medicine Vice Chief of Internal Medicine Baylor University Medical Center Dallas, TX

Director, Center for Genetic Medicine Elizabeth J. Ward Professor of Genetic Medicine Professor of Medicine (Cardiology) and Biochemistry and Molecular Genetics Northwestern University Feinberg School of Medicine Chicago, IL

Margo B. Minissian, PhD, ACNP, FAHA, FNLA

Patrick M. Moriarty, MD

Alanna A. Morris MD, MSc, FHFSA, FACC

Martin G. Myers, Jr., MD, PhD

Nurse Scientist Cardiology Nurse Practitioner Clinical Lipid Specialist Barbra Streisand Womenâ&#x20AC;&#x2122;s Heart Center, Cedars-Sinai Heart Institute Los Angeles, CA

Assistant Professor of Medicine, Division of Cardiology Emory University Clinical Cardiovascular Research Institute Atlanta, GA

Biff F. Palmer, MD Professor of Internal Medicine University of Texas Southwestern Medical Center Dallas, TX

Director, Atherosclerosis/LDL-Apheresis Center Professor of Medicine University of Kansas Medical Center Kansas City, KS

Marilyn H. Vincent Professor of Diabetes Research Professor, Department of Internal Medicine and Molecular & Integrative Physiology Director, Michigan Diabetes Research & Training Center University of Michigan Ann Arbor, MI

Gurusher S. Panjrath, MD, FACC, FAHA Director, Heart Failure and Mechanical Circulatory Support Program Associate Professor of Medicine George Washington University School of Medicine Washington DC

Aldo J. Peixoto, MD

Anne L. Peters, MD

Professor of Medicine (Nephrology) Yale School of Medicine Associate Chair for Ambulatory Operations and Quality Department of Internal Medicine Clinical Chief, Section of Nephrology Director, Yale Hypertension Center New Haven, CT

Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California Los Angeles, CA

www.cardiometabolichealth.org

Eric David Peterson, MD, MPH, FAHA, FACC

Ileana L. PiĂąa, MD, MPH, FAHA, FACC

Fred Cobb, MD, Distinguished Professor of Medicine Duke Clinical Research Institute Durham, NC

Clinical Prof of Medicine, Central Michigan University Director CVD Research and Academic Affairs Regional and National Director of Heart Failure Detroit Medical Center Detroit, MI

Jonathan D. Rich, MD, FACC, FHFSA*

Julio Rosenstock, MD

Associate Professor of Medicine Northwestern University, Feinberg School of Medicine Medical Director, Mechanical Circulatory Support Program Program Director, Advanced Heart Failure and Transplant Fellowship Bluhm Cardiovascular Institute, Northwestern Memorial Hospital Chicago, Illinois

Director, Dallas Diabetes and Endocrine Center Clinical Professor of Medicine University of Texas Southwestern Medical Center Dallas, TX

Joshua M. Stolker, MD*

Raymond R. Townsend, MD

Saint Louis University St. Louis, Missouri

Director, Hypertension Program, Hospital of the University of Pennsylvania Professor of Medicine at the Hospital of the University of Pennsylvania Philadelphia, PA

Mintu P. Turakhia, MD, MAS

Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE

Associate Professor Executive Director, Center for Digital Health Stanford University School of Medicine Stanford, CA Chief of Cardiac Electrophysiology VA Palo Alto Health Care System Palo Alto, CA

Diabetes Specialist Clinica La Esperana Albuquerque, NM

Tracy Y. Wang, MD, MHS, MSc

Patrick Wayte, MBA

Associate Professor Director, Health Services Research Duke University Durham, NC

Senior Vice President, Center for Health Technology & Innovation American Heart Association â&#x20AC;&#x201C; National Center Dallas, TX

Michael A. Weber, MD

Matthew R. Weir, MD

Professor of Medicine State University of New York Downstate College of Medicine Brooklyn, NY

Professor and Director Division of Nephrology University of Maryland School of Medicine Baltimore, MD

Holly Wyatt, MD University of Colorado Anschutz Health and Wellness Center The Wellness Clinic at the University of Colorado Anschutz Health and Wellness Center Associate Professor, CU School of Medicine Division of Endocrinology, Metabolism and Diabetes Aurora, CO

16 www.cardiometabolichealth.org

*Professional Medical Education (PME) presenter **PME presenter and General Session/CME Symposium presenter

The 2019 Cardiometabolic Health Congress gratefully acknowledges the following PLATINUM MEDIA

ASSOCIATION PARTNERS

18 www.cardiometabolichealth.org

MEDIA PARTNERS

EXHIBITOR INDEX

GRAND HORIZON ABC

EXHIBIT BREAK HOURS Friday, October 11 Saturday, October 12 :00 10

:00 11

:00 12

1:0

2:0

3:0

4:0

5:0

6:0

FRIDAY, OCTOBER 11

SATURDAY, OCTOBER 12

Morning Break

10:15 am – 11:15 am

Morning Break

10:00 am – 11:00 am

Afternoon Break

2:25 pm – 3:25 pm

Afternoon Break

2:15 pm – 3:15 pm

Welcome Reception

5:25 pm – 6:25 pm

Happy Hour

5:20 pm – 6:20 pm

COMPANY NAME Aegerion Pharmaceuticals Amarin Pharma, Inc. American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) American Society for Preventive Cardiology Amgen Arbor Pharmaceuticals AstraZeneca Bentham Science Publishers Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA Cardiology Today and Endocrine Today by Healio Cleveland HeartLab - Quest Diagnostics Daiichi Sankyo, Inc. Med Learning Group Medicure Pharma Merck & Co., Inc. Novo Nordisk – Diabetes Novo Nordisk – Obesity Management Patient Advocate Foundation Regeneron / Sanofi Salix Pharmaceuticals SpectraCell Laboratories UTM Healthcare, LLC www.cardiometabolichealth.org

Aegerion Pharmaceuticals One Main Street, Suite 800 Cambridge, MA 02142 www.novelion.com

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

Amarin Pharma, Inc. 1430 Route 206, Suite 200 Bedminster, NJ 07921 908-719-1315 www.amarincorp.com

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information visit www.amarincorp.com.

American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) 330 N. Wabash Avenue Suite 2000 Chicago, IL 60611 312-321-5146 www.aacvpr.org

Founded in 1985, the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) is dedicated to our mission of reducing morbidity, mortality and disability from cardiovascular and pulmonary disease through education, prevention, rehabilitation, research and disease management. Central to the core mission is improvement in quality of life for patients and their families. We are a multidisciplinary professional association comprised of health professionals who serve in the field of cardiac and pulmonary rehabilitation. Members include cardiovascular and pulmonary physicians, nurses, exercise physiologists, physical therapists, behavioral scientists, respiratory therapists, dietitians and nutritionists.

American Society for Preventive Cardiology

450-106-SR13 N, #140 450-106-SR13 N, #140 Saint Johns, FL 32259 904-217-7407 www.aspconline.org The American Society for Preventive Cardiology (ASPC) is a multidisciplinary organization dedicated to the prevention of cardiovascular disease. If your work lies within the boundaries of preventive cardiology, ASPC membership is a powerful way to improve your scope of activity and further your career objectives. Visit Booth T111 to learn about What ASPC Membership can do for you.

Amgen

One Amgen Center Drive Thousand Oaks, CA 91320 805-447-1000 www.amgen.com Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Arbor Pharmaceuticals 6 Concourse Parkway, Ste 1800 Atlanta, GA 30328 678-334-2420 www.arborpharma.com

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital, neuroscience, and pediatric markets. Visit www.arborpharma.com or send email inquiries to info@arborpharma.com Arbor Pharmaceuticals, LLC 6 Concourse Parkway, Ste 1800 Atlanta, GA 30328 Tel: 678-334-2420 Fax: 470-235-2403. www.cardiometabolichealth.org

AstraZeneca

1800 Concord Pike Wilmington, DE 19803 1-800-236-9933 www.astrazeneca.com About AstraZeneca in CV, Renal & Metabolism (CVMD) CV, renal and metabolism together form one of AstraZeneca’s main therapy areas and a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVMD diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CV health for millions of patients worldwide.

Bentham Science Publishers 117 S EUCLID AVE Oak Park, IL 60302 708-308-4203 www.benthamscience.com

Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at https://benthamscience.com/. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here https://ebooks.benthamscience. com/. Bentham Science is offering 20% discounts on purchasing eBooks and subscriptions on Journals to delegates attending the conference. TO AVAIL, QUOTE “BSPCNF2019” at http://www.eurekaselect.com/ or email at marketing@benthamscience.net. For more information https://benthamscience.com/browse-bysubject/medicine/sub-category/cardiology/

22 www.cardiometabolichealth.org

Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA 900 Ridgebury Road Ridgefield, CT 06877 203-798-9988 www.jardiance.com

Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you to Cardiometabolic Health Congress and look forward to the opportunity to share the latest clinical information on our products. Visit http:// us.boehringer-ingelheim.com or www.lilly.com. Follow us on twitter at @boehringerus. Our Diabetes Alliance also welcomes you to visit www.jardiance.com.

Cardiology Today and Endocrine Today by Healio 6900 Grove Rd. Thorofare, NJ 08086 856-848-1000 www.healio.com

CARDIOLOGY TODAY AND ENDOCRINE TODAY are reporting LIVE at CMHC! In print and online, you’ll get the latest meeting coverage along with expert perspective from our renowned Editorial Boards and other leading clinicians. Explore videos, In the Journals and resources that are relevant to your practice. Stop by our booth for a free issue of Cardiology Today and Endocrine Today.

Cleveland HeartLab - Quest Diagnostics 500 Plaza Drive Secaucus, NJ 07094 603-315-1259 www.questdiagnostics.com

The Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence is committed to advancing the prevention of the most costly and debilitating cardiovascular events. Our broadly available comprehensive menu of novel biomarkers spanning the cardiometabolic continuum provides deeper insights into hidden risk that go well beyond traditional testing. By combining this enhanced diagnostic capability with solutions to help engage patients in their care, we empower people to take action to reduce cardiometabolic risk, while improving long-term health outcomes.

Daiichi Sankyo, Inc.

Merck & Co., Inc.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group and is focused on the development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

211 Mount Airy Road Basking Ridge, NJ 07920 908-992-6400 www.daiichisankyo.com

Med Learning Group

3101 W Dr MLK Jr Blvd Tampa, FL 33607 845-304-4520 www.medlearninggroup.com Med Learning Group focuses on developing and implementing education that improves healthcare practitioners’ ability to provide optimal care to patients. Visit MLG at Booth 204 to be taken through a Virtual Reality tour of hypercholesterolemia. The VR learning booth includes three Virtual Reality themes, a case study on iPads, Quality Improvement Personalized Posters, Augmented Reality and downloadable clinical practice animations.

Medicure Pharma 2-1250 Waverley St Winnipeg, MB R3T6C6 204-487-7412 www.medicure.com

Medicure is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics for the U.S. market. Medicure strives to become a leading specialty pharmaceutical company in the U.S. market by improving people’s lives through our growing product portfolio of acute cardiovascular products and innovative commercial model. Our commitment to service, partnership and integrity are what sets us apart.

2000 Galloping Hill Rd. Kenilworth, NJ 07033 908-740-4000 www.merck.com

Novo Nordisk - Diabetes 800 Scudders Mill Road Plainsboro, NJ 08536 609-786-8321 www.novonordisk-us.com

Novo Nordisk, a global leader in diabetes care, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations. We’re working toward a future where fewer people get diabetes, everyone is diagnosed, and all patients receive adequate treatment.

Novo Nordisk – Obesity Management 800 Scudders Mill Road Plainsboro, NJ 08536 800-727-6500 www.novonordisk-usa.com

For more than 90 years, Novo Nordisk, a global leader in health care, has been discovering and developing innovative medicines to help people with chronic diseases lead longer, healthier lives.

Patient Advocate Foundation 421 Butler Farm Road Newport News, VA 23666 1-800-532-5274 www.patientadvocate.org

Patient Advocate Foundation provides direct services to patients with chronic, life threatening and debilitating diseases to help eliminate obstacles in access to quality healthcare. A comprehensive portfolio delivers educational, financial and insurance resources, featuring Matters of the Heart is available in one easy-to-access online location. www.cardiometabolichealth.org

Regeneron / Sanofi

SpectraCell Laboratories

Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patientsâ&#x20AC;&#x2122; needs. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

SpectraCell Laboratories, Inc. is a leading clinical laboratory specializing in personalized disease prevention and management solutions. Our pioneering nutritional and cardiometabolic testing, driven by state-of-the-art technology, assesses a spectrum of risk factors and biomarkers for optimum wellness. Through our dedication to research and development, SpectraCell also provides innovative solutions for hormone health and genetics. We are committed to providing scientific excellence, superior disease prevention and management solutions, and the highest quality of service to clients and their patients worldwide.

777 Old Saw Mill River Road Tarrytown, NY 10591 914-847-7000 www.regeneron.com

Salix Pharmaceuticals 400 Somerset Corporate Blvd. Bridgewater, NJ 08807 215-602-8031 www.salix.com

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed and marketed innovative products to improve patientsâ&#x20AC;&#x2122; lives and arm healthcare providers with lifechanging solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.

24 www.cardiometabolichealth.org

10401 Town Park Drive Houston, TX 77072 800-227-5227 www.spectracell.com

UTM Healthcare, LLC One Hudson City Centre Hudson, NY 12534 888-892-8068 www.utmhealthcare.com

UTMHealthcare provides a suite of integrated solutions that provide software and hardware for communicating critical real-time health data to healthcare providers in a completely secure and easy to use way. Our RPM products are HIPAA compliant remote patient monitoring systems facilitating patient-friendly home care monitoring. They provide efficient and simple solutions that benefits both patients and providers. Patients can remain in their homes while providing alerts to their own medical teams with essential, time-sensitive data for managing chronic conditions and hence reducing the need for emergency room visits and hospital admissions.

PME Lunch Symposium

PROFESSIONAL MEDICAL EDUCATION (NON-CME)

Thursday, October 10, 2019 12:05pm – 1:05pm Great Lakes (AB) Ballroom Reviewing A1C and Cardiovascular Safety Data in T2D Therapies Joshua M. Stolker, MD An endocrinologist/diabetologist or a cardiologist discuss a multidisciplinary approach to the management of adults living with type 2 diabetes (T2D). The presenter will review the clinical trial program for two GLP-1 RA agents, as well as present the CVOT data. Visit the Novo Nordisk booth for more information. Financial support for this program is provided by Novo Nordisk.

PME Light Bites Symposium

Thursday, October 10, 2019 4:15pm – 5:15pm Great Lakes (AB) Ballroom Cardiovascular Patient Cases Eliot A. Brinton, MD

Round out your CMHC educational experience by attending Professional Medical Education/ Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/ companies.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. Sponsored by Amgen, Inc.

26 www.cardiometabolichealth.org

PME Light Bites Symposium

PME Dinner Symposium

Thursday, October 10, 2019

Friday, October 11, 2019

5:20pm – 6:20pm Great Lakes (AB) Ballroom Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study

6:30pm – 7:30pm Great Lakes (AB) Ballroom Understanding the Clinical Implications of Heart Failure and Renal Dysfunction in Your Patients With Type 2 Diabetes

George Grunberger, MD Despite the benefits of LDL-C lowering, many patients on statin therapy with elevated triglycerides remain at risk for cardiovascular (CV) disease. In this presentation, Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study, the results from the CV outcomes trial, REDUCE-IT™, will be reviewed. REDUCE-IT compared the number of major adverse CV events in 8179 patients with statin-controlled LDL-C, elevated triglycerides, and other CV risk factors including established CVD and diabetes. Visit the Amarin Pharma, Inc. booth for more information.

Peter A. McCullough, MD, MPH The objectives of this presentation are to review the scope and impact of type 2 diabetes (T2D) by focusing on the risk and burden of heart failure (HF). An overview of HF and risk factors for HF in T2D will be discussed. Also discussed will be the assessment of risk and improving diagnosis of HF in patients with T2D in the primary care setting while recognizing that renal and cardiovascular disease are closely interconnected in patients with T2D. Please join us for this event. Sponsored by AstraZeneca.

Sponsored by Amarin Pharma, Inc.

PME Light Bites Symposium PME Dinner Symposium

Thursday, October 10, 2019 6:30pm – 7:30pm Great Lakes (AB) Ballroom Jardiance® (empagliflozin) tablets: Data from the comprehensive clinical development program Jonathan D. Rich, MD, FACC, FHFSA This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the faculty questions about the data presented. Sponsored by Boehringer-Ingelheim.

Saturday, October 12, 2019 6:30pm – 7:15pm Great Lakes (EF) Ballroom Understanding CKD in T2D: The Risks, Recognition, and Clinical Management Peter A. McCullough, MD, MPH; Luiza Caramori, MD Chronic kidney disease (CKD) develops in a substantial proportion of patients with diabetes and significantly increases risk for adverse cardiovascular and renal outcomes. Multiple factors can contribute to the development and progression of CKD, although the precise etiology continues to evolve. The deleterious impact of CKD progresses over time, but consequences emerge in early stage disease, raising the importance of adherence to guideline recommendations for diagnostic screening, continued monitoring, and coordination of care across specialties for patients with CKD. Sponsored by Bayer.

www.cardiometabolichealth.org

2019 CMHC Annual Accreditation ACTIVITY TITLE: 14th Annual Cardiometabolic Health Congress ACTIVITY DATE: October 10-13, 2019 | Chicago, Illinois TARGET AUDIENCE The CMHC is designed for advanced level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk including cardiologists, endocrinologists, diabetologists, lipidologists, pharmacists, primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals. PROGRAM OVERVIEW The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease currently affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden is expected to increase. This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The Cardiometabolic Health Congress (CMHC) presents an especially valuable venue for this educational outreach bringing together faculty members from multiple disciplines, including cardiology, endocrinology, and primary care, to lead sessions that foster a collaborative, multidisciplinary approach to care. The 2019 CMHC will translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing cardiovascular and metabolic disorders. The goal is to provide the medical community with evidence-based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk. EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: • Discuss the interrelationships among cardiometabolic risk factors and their impact on the development of cardiometabolic diseases, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease. • Interpret the latest evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease. • Outline strategies aimed at timely screening and prevention of cardiometabolic disease, including biomarkers, imaging, genetic risk assessment, and lifestyle modifications. • Develop individualized treatment regimens for patients with cardiometabolic disease based on the efficacy and safety of current and new pharmacotherapies, patient comorbidities and preferences to optimize outcomes. • Summarize recent evidence for emerging therapies in order to stay current with the most recent updates in the cardiometabolic field. • Employ strategies that promote patient-centered care, including patient communication and education, in order to optimize adherence to treatment regimens.

28 www.cardiometabolichealth.org

• Recognize the role of real-world evidence, data science, and technology in aiding and improving care for cardiometabolic diseases. JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CONTINUING MEDICAL EDUCATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 22 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CONTINUING PHARMACY EDUCATION Postgraduate Institute for Medicine designates this continuing education activity for 22 contact hour(s) (2.2 CEUs) of the Accreditation Council for Pharmacy Education. This is an application-based activity. Universal Activity Number (UAN): JA4008162-9999-19-897-L01-P CONTINUING NURSING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 21.9 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. CONTINUING DIETICIAN EDUCATION Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 22 Continuing Professional Education units (CPEUs) for completion of this activity. This is a Level II activity. ABIM MOC CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. SCOPE CERTIFICATION

The World Obesity/Clinical Care committee decided that the further learning value, quality and structure of the 14th Annual CMHC comply with Specialist Certification of Obesity Professional Education (SCOPE) principles. This event has been accredited with 4 SCOPE Points which count towards SCOPE Certification. SCOPE Certification is conferred by the World Obesity Federation and is the internationally-recognized standard of excellence in obesity

management. SCOPE Certification is awarded to health professionals with obesity management experience who have earned 12 SCOPE points. For questions regarding SCOPE points, please contact info@cardiometabolichealth.org. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Faculty Disclosures will be provided on the mobile app. Planners and Managers The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose. DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. EDUCATIONAL GRANT SUPPORT The 14th Annual CMHC is supported in part by an independent and unrestricted educational grant from Merck. REQUEST FOR CREDIT Learners may earn up to a maximum of 28.75 AMA/ACPE/ABIM MOC, 28.4 ANCC, or 30 CDR credit hours by attending all General Sessions and CME Satellite Symposia. If you wish to receive acknowledgment for completing all activities and earn maximum credit, please complete each evaluation on www. cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID below. Upon registering and completing the activity evaluation for each course, a certificate will be made available immediately. For Pharmacists: Please complete each evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID below. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.

Course Title and Date

Course ID

CMHC General Sessions – October 10-13

14194

CME Breakfast Symposium A – October 11, 6:30 – 7:45 am Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras

14637

CME Lunch Symposium A – October 11, 12:20 – 1:35 pm Reducing Cardiovascular Risk: A Paradigm Shift in T2DM Management

14633

CME Breakfast Symposium A – October 12, 6:30 – 7:45 am The Potassium Dilemma in HF and CKD: Challenges and Advancements in the Management of Hyperkalemia

14530

CME General Session – October 12, 8:30 – 9:00 am Treatment of High-Risk Patients with CVD and Elevated TGs: REDUCE-IT and Beyond

14531

CME Lunch Symposium A – October 12, 12:00 – 1:15 pm Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction

14290

CME Lunch Symposium B – October 12, 12:00 – 1:15 pm Advances in Iron Repletion Therapy: Addressing the Burden of Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life

14683

CME Dinner Symposium – October 12, 7:20 – 8:35 pm Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

14635

Please visit the Satellite Symposia sections of this Conference Guide for additional information.

www.cardiometabolichealth.org

proud media partner of the cardiometabolic health congress Cardiology Today and Endocrine Today are reporting live from the 2019 Cardiometabolic Health Congress. Get up-to-the-minute news and perspective straight from the podium on Healio.com, the online home of Cardiology Today and Endocrine Today. In print and online, you’ll get the latest meeting coverage along with expert perspective from our renowned Editorial Boards and other leading clinicians.

Cardiology and Endocrinology covered. Pediatric anticoagulant approved 19

Pulsed field ablation safe 30

Risk of energy drinks 31

Healio.com/Cardiology

Volume 22 • Number 7 JULY 2019

Meeting News: ADA 16

Victoza approved for children 34

Web Watch 35

Healio.com/Endocrinology

Volume 17 • Number 7 JULY 2019

Daily news

Carl J. Pepine, MD, Chief Medical Editor

C L I N I C A L

N E W S

O N

D I A B E T E S

A N D

E N D O C R I N E

D I S O R D E R S

COVER STORY MEETING NEWS: NLA

Michael J. Blaha, MD, MPH, from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, said e-cigarettes contain known CV toxins and use must be monitored closely.

ORION-3: Inclisiran safely reduces LDL by more than 50%

Electronic cigarettes, or e-cigarettes, have become increasingly popular since they entered the market in 2006. Use of these alternative devices continues to grow. According to recent CDC data, 2.8% of U.S. adults reported using an e-cigarette in 2017. A big concern is the growing use of e-cigarettes in children and teenagers. In 2018, 3.6 million U.S. middle and high school students reported recent use of e-cigarettes, according to the CDC. Although research in this area is sparse, emerging data have shown the potential benefit of e-cigarettes such as Juul, in terms of cigarette smoking cessation. In a study published in The New England Journal of Medicine in January, more participants assigned e-cigarettes for smoking cessation abstained from smoking at 1 year compared with a control group in which patients could choose their own nicotine replacement therapy (18% vs. 9.9%; RR = 1.83; 95% CI, 1.3-2.58). However, benefits to cigarette smoking cessation aside, Cover story continues on page 12

VASCULAR MEDICINE All Vascular Medicine articles start on page 8

ORION-3 continues on page 26

TRIAL SCORECARDS ImpACT24-B Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24-Hour Window Design:

randomized, parallel-assignment, tripleblind Patients: 1,078 Centers: 73 Countries: worldwide RESULTS: See page 11

AHA: Despite improvements in HIV treatment, CVD risk elevated Antiretroviral therapy for patients with HIV has made the disease less fatal, but it has increased the rates of CVD in this patient population, according to an American Heart Association scientific statement published in Circulation. “Over the last 20 years or so, we’ve learned a lot about the increased cardiovascular risk in HIV,” Chris T. Longenecker, MD, assistant professor of medicine at Case Western Reserve University, Cardiology Today Next Gen InChris T. Longenecker novator and member of the writing group, said in an interview. “We’ve done studies of mechanisms and learned a lot about inflammation and immune activation, but despite this and despite some ev-

Inclisiran injections administered twice per year safely reduced LDL by at least 50% out to 3 years, according to a late-breaking clinical trial presented at the National Lipid Association Scientific Sessions. “That actually translates into what is in my eyes as a clinician a totally new therapy that you only have to inject twice a year, and there is absolutely nothing like this,” John J. Kastelein, MD, PhD, professor of medicine and strategic chair of genetics of cardiovascular disease, department of vascular medicine

Microbiome’s ‘untapped extra genome’ may hold clues to prevent, treat diabetes The human gut microbiome contains tens of Microbiome researchers are only beginning to trillions of microorganisms, including at least understand the greater influence of gut microor1,000 different species of known bacteria with ganisms on the human body, which research sugmore than 3 million genes. The microbiota that gests affect the pathogenesis of conditions ranginhabit the intestines are esing from obesity, asthma and sential for key metabolic procardiovascular disease to type “There is this untapped 1 and type 2 diabetes. As new cesses, such as the breakdown extra genome [of the of indigestible dietary fibers, sequencing techniques are enmicrobiome], and the biosynthesis of amino acabling a more comprehensive we can make smallids and the production of neumapping of bacteria in the gut, rotransmitters and hormones. researchers are discovering molecule inhibitors “There is more and more that bacterial genomes, and that selectively target evidence that the microbiome not individual microbes, may bacterial enzymes is an active metabolic comparthold the clues for targeting disand receptors or ment of the human body, in the eases like type 2 diabetes. transporters.” way we think of the liver or the “Until recently, a lot of em— J. MARK BROWN, PHD kidney as metabolic organs,” phasis has been placed on Martin J. Blaser, MD, director looking at bacteria based on of the Center for Advanced Biotechnology and their names: E. coli, Prevotella, Akkermansia,” Medicine and the Henry Rutgers Chair of the Hu- C. Ronald Kahn, MD, the Mary K. Iacocca man Microbiome at Rutgers, The State University Professor of Medicine at Harvard Medical School of New Jersey, told Endocrine Today. “As such, it and chief academic officer of the Joslin Diabetes may affect energy production, drug metabolism Center, told Endocrine Today. “What we now know and different aspects of hormonal homeostasis — is that even bacteria that have the same names may and there seems to be evidence for all of these.” Cover Story continues on page 10

Physician perspective

Lack of microbial diversity, which is greatly influenced by diet, is a common thread among metabolic diseases, according to Ruchi Mathur, MD, FRCP.

MEETING NEWS: SCAI

idence that the risk may be declining over time, there are still significant disparities in care. We now need to turn our attention towards addressing these disparities. This document helps make that clear for the community.” Patients living with HIV have been found in several studies to have an excess risk for MI compared with those without HIV, which may be associated with HIVrelated viremia, immune dysfunction, lower CD4 counts and a lower CD4/CD8 ratio, Matthew J. Feinstein, MD, MSc, assistant professor of medicine and preventive medicine at Northwestern University Feinberg School of Medicine and chair of the writing group, and colleagues wrote in the scientific statement. This increased risk may also be seen in patients with sustained HIV viral suppression or have few CV factors.

All Meeting News: SCAI articles start on page 22

FFR changes treatment plan after angiography in more than 30% of cases

Endocrine today BY THE NUMBERS

Among patients with stable CAD or ACS who were given an initial treatment plan after angiography, the plan changed in more than 30% after fractional flow reserve was performed, according to results of the PRESSUREwire study. In addition, FFR did not cause any serious adverse events, researchers reported at the Society for Cardiovascular Angiography and Interventions Scientific Sessions. FFR continues on page 23

HIV continues on page 8 For related story, turn to page 14

D2d: Vitamin D fails to prevent type 2 diabetes Adults with prediabetes assigned to daily vitamin D supplementation for 2.5 years were just as likely to develop type 2 diabetes during followup as similar patients assigned to placebo, regardless of baseline vitamin D status, according to study data presented and published in The New England Journal of Medicine. Findings from recent observational studies have suggested that vitamin D has extraskeletal benefits, including for diabetes prevention, whereas sales DIABETES

INTERVENTION

PHARMACOLOGY CONSULT

IN THE JOURNALS

TAVR increases risk for mortality, bleeding in end-stage renal disease

Out of the loop: Augmenting diuresis with SGLT2 inhibitors in HF

Neladenoson not beneficial in HFpEF

After 20-year increase, new diabetes cases decline 35%.

PAGE 7

PAGE 14

PAGE 33

PAGE 3

A SLACK Incorporated® publication

CT0719_1, 12-13.indd 1

Meeting coverage Photo by Jo Auger. Printed with permission.

Source: Brian H. Waters, Johns Hopkins Medicine. Printed with permission.

Cardiologists grapple with potential CV risks posed by e-cigarettes

COVER STORY

All Meeting News: NLA articles start on page 26

of over-the-counter vitamin D rose sharply between 2001 and 2009 as media outlets reported on such findings, Myrlene A. Staten, MD, a project scientist with the National Institute of Diabetes and Digestive and Kidney Diseases at the NIH, said during a presentation on the Vitamin D and Type 2 Diabetes (D2d) trial at the American Diabetes Association Scientific Sessions. “It became important to determine, is all of this supplemental vitamin D that people BONE/MINERAL METABOLISM FRAX data suggest no increased fracture risk with aromatase inhibitor use. PAGE 14

are taking warranted?” Staten said. “The NIDDK and the Office of Dietary Supplements and ADA supported this trial to assess whether people at risk for type 2 diabetes, if they received vitamin D at 4,000 IU per day, would this reduce the rate of progression to type 2 diabetes?” Staten and colleagues analyzed data from 2,423 participants aged at least 30 years with a BMI between 24 kg/m² and 42 kg/m² who met at least two D2d continues on page 16

THYROID High-activity radioiodine therapy acceptable for older adults with thyroid cancer. PAGE 31

CME Video

A SLACK Incorporated® publication

6/24/2019 3:18:40 PM

ET0719_1,10-12.indd 1

7/2/2019 2:10:57 PM

CME Breakfast Symposium A FRIDAY, OCTOBER 11

6:30 â&#x20AC;&#x201C; 7:45 AM | GREAT LAKES (AB) BALLROOM

Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated in

recent clinical trial results, and several phase III trials are ongoing. During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify patients at high-risk, and the current management of DKD. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

George L. Bakris, MD (Chair)

Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Rajiv Agarwal, MD

Professor of Medicine Indiana University School of Medicine & VA Medical Center Indianapolis, IN

Ileana L. PiĂąa, MD, MPH, FAHA, FACC

Clinical Prof of Medicine, Central Michigan University Director CVD Research and Academic Affairs Regional and National Director of Heart Failure Detroit Medical Center Detroit, MI 32 www.cardiometabolichealth.org

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Review the association and the pathophysiology between T2D and CKD, and the impact of concomitant CKD and T2D on patient outcomes • Employ the diagnostic criteria according to evidencebased guidelines for DKD in patients with T2DM at risk for kidney disease progression • Utilize current treatment options for patients with DKD based on identified benefits and risks, and current guideline recommendations • Review the efficacy and safety of emerging DKD treatments based on the latest evidence

6:30 – 6:35 am Overview George L. Bakris, MD (Chair)

EDUCATIONAL GRANT SUPPORT This satellite symposium is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

JOINT PROVIDERSHIP STATEMENT

6:35 – 6:50 am Understanding the Pathophysiologic Link Between Cardiovascular Disease and Diabetic Kidney Disease George L. Bakris, MD (Chair) 6:50 – 7:05 am Current Treatment Options for DKD Ileana L. Piña, MD, MPH 7:05 – 7:25 am Emerging targets and therapeutic options for DKD Rajiv Agarwal, MD 7:25 – 7:40 am

Patient Case, Discussion, and Audience Q&A Presenter: George L. Bakris, MD Panel: All faculty

7:40 – 7:45 am Conclusions George L. Bakris, MD (Chair)

content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality In support of improving patient care, this activity in healthcare and not a specific proprietary has been planned and implemented by the business interest of a commercial interest. Postgraduate Institute for Medicine and Tarsus Faculty disclosures may be found on the CMHC Cardio Inc. dba Cardiometabolic Health Congress Mobile App. (CMHC). Postgraduate Institute for Medicine is The PIM planners and managers have nothing to jointly accredited by the Accreditation Council disclose. The CMHC planners and managers have Successful completion of this CME activity, for Continuing Medical Education (ACCME), the nothing to disclose. which includes participation in the evaluation Accreditation Council for Pharmacy Education DISCLOSURE OF UNLABELED USE (ACPE), and the American Nurses Credentialing component, enables the participant to earn This educational activity may contain discussion Center (ANCC), to provide continuing education up to 1.25 MOC points in the American Board of published and/or investigational uses of of Internal Medicine’s (ABIM) maintenance of for the healthcare team. agents that are not indicated by the FDA. The certification (MOC) program. Participants will PHYSICIAN CREDIT DESIGNATION planners of this activity do not recommend earn MOC points equivalent to the amount of The Postgraduate Institute for Medicine desigthe use of any agent outside of the labeled CME credits claimed for the activity. It is the nates this live activity for a maximum of 1.25 indications. The opinions expressed in the educaAMA PRA Category 1 Credits™. Physicians should CME activity provider’s responsibility to submit participant completion information to ACCME for tional activity are those of the faculty and do not claim only the credits commensurate with the necessarily represent the views of the planners. the purpose of granting ABIM MOC credit. extent of their participation in the activity. Please refer to the official prescribing information REQUEST FOR CREDIT NURSING CONTINUING EDUCATION for each product for discussion of approved If you wish to receive acknowledgment for The maximum number of hours awarded for indications, contraindications, and warnings. this Continuing Nursing Education activity is 1.2 completing this activity, please complete the DISCLAIMER evaluation on www.cmeuniversity.com. On contact hours. Pharmacotherapy contact hours Participants have an implied responsibility to the navigation menu, click on “Find Post-test/ for Advanced Practice Registered Nurses will be use the newly acquired information to enhance Evaluation by Course” and search by course ID designated on your certificate. patient outcomes and their own professional PHARMACIST ACCREDITATION STATEMENT 14637. Upon registering and completing the activity evaluation, your certificate will be made development. The information presented in this Postgraduate Institute for Medicine designates activity is not meant to serve as a guideline for this continuing education activity for 1.25 contact available immediately. hour(s) (.125 CEUs) of the Accreditation Council For Pharmacists: Please complete the evaluation patient management. Any procedures, medicaon www.cmeuniversity.com. On the navigation tions, or other courses of diagnosis or treatment for Pharmacy Education. discussed or suggested in this activity should not menu, click on “Find Post-test/Evaluation by This is an application-based activity. Universal be used by clinicians without evaluation of their Course” and search by course ID 14637. Upon Activity Numbers (UAN): JA4008162-9999-19patient’s conditions and possible contraindiregistering and completing the activity evalua899-L01-P cations and/or dangers in use, review of any tion, your transcript information will be sent to Pharmacists have up to 30 days to complete applicable manufacturer’s product information, the evaluation and claim credit for participation the NABP CPE Monitor Service. and comparison with recommendations of other DISCLOSURE OF CONFLICTS OF INTEREST so that information can be submitted to CPE authorities. Postgraduate Institute for Medicine (PIM) reMonitor as required. quires instructors, planners, managers, and other DIETICIAN ACCREDITATION STATEMENT individuals who are in a position to control the Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity. This is a Level II activity. ABIM MOC CERTIFICATION

www.cardiometabolichealth.org

CME Lunch Symposium A FRIDAY, OCTOBER 11

12:20 â&#x20AC;&#x201C; 1:35 PM | GREAT LAKES (AB) BALLROOM

Reducing Cardiovascular Risk: A Paradigm Shift in T2DM Management This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Although the association between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) remains complex, there is a dire need for comprehensive strategies to reduce the risk of adverse CV events in patients with T2DM. In recent years, several antihyperglycemic agents have shown that they not only improve glycemic parameters, but also reduce the risk of cardiovascular events, as demonstrated in multiple cardiovascular outcome trials (CVOT). These trials, originally designed to demonstrate CV safety, have provided valuable practicechanging insights that have shifted the focus of T2DM care

beyond glucose control into CV risk management and prevention. This symposium will provide clinicians with up-to-date information on the latest outcome trials, how to interpret their clinical practice implications and incorporate this evidence when individualizing therapy for patients with T2DM and cardiovascular risk. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Robert H. Eckel, MD (Chair)

Lawrence Blonde, MD

Director, Ochsner Diabetes Clinical Research Unit Frank Riddick Diabetes Institute Department of Endocrinology Ochsner Medical Center New Orleans, LA

Tracy Y. Wang, MD, MHS, MSc Associate Professor Director, Health Services Research Duke University Durham, NC

34 www.cardiometabolichealth.org

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Discuss the underlying links between CVD and T2DM and the burden of CVD in T2DM patient outcomes • Interpret the current evidence from CV outcomes trials with antihyperglycemic agents, including SGLT-2 inhibitors and GLP-1 RAs, and their practice implications in patients with T2DM and CVD • Develop individualized treatment regimens based on the latest evidence and guideline recommendations in order to minimize cardiovascular risk in patients with T2DM

12:20 – 12:25 pm Overview Robert H. Eckel, MD (Chair)

EDUCATIONAL GRANT SUPPORT

1:05 – 1:25 pm

Patient Case All faculty

1:25 – 1:35 pm

Conclusions and Audience Q&A All faculty

This satellite symposium is supported by an educational grant from Novo Nordisk. JOINT PROVIDERSHIP STATEMENT

12:25 – 12:35 pm C V Comorbidities in T2DM and Their Impacts Tracy Y. Wang, MD 12:35 – 12:55 pm Review of Recent CVOT Trials Lawrence Blonde, MD 12:55 – 1:05 pm What Have We Learned from Trials and Individualization of Therapy? Robert H. Eckel, MD (Chair)

the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the This activity has been planned and implemented Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 in accordance with the accreditation requireContinuing Professional Education units (CPEUs) ments and policies of the Accreditation Council for completion of this activity. for Continuing Medical Education (ACCME) through the joint providership of the Annenberg This is a Level II activity. ABIM MOC CERTIFICATION Center for Health Sciences at Eisenhower and Cardiometabolic Health Congress. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing Successful completion of this CME activity, medical education for physicians. which includes participation in the evaluation PHYSICIAN CREDIT DESIGNATION component, enables the participant to earn The Annenberg Center for Health Sciences at up to 1.25 MOC points in the American Board Eisenhower designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will Physicians should claim only the credits commensurate with the extent of their participation earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the in the activity. CME activity provider’s responsibility to submit NURSING CONTINUING EDUCATION Annenberg Center for Health Sciences is accredit- participant completion information to ACCME for ed as a provider of continuing nursing education the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT by the American Nurses Credentialing Center’s If you wish to receive acknowledgment for Commission on Accreditation. completing this activity, please complete the Credit Designation evaluation on www.cmeuniversity.com. On 1.2 contact hours may be earned for successful the navigation menu, click on “Find Post-test/ completion of this activity. Evaluation by Course” and search by course ID Pharmacotherapy contact hours for Advance 14633. Upon registering and completing the Practice Registered Nurses to be determined. PHARMACIST ACCREDITATION STATEMENT activity evaluation, your certificate will be made available immediately. The Annenberg Center for Health Sciences at Eisenhower is accredited by For Pharmacists: Please complete the evaluation the Accreditation Council for Pharmacy on www.cmeuniversity.com. On the navigation Education as a provider of continuing menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14633. Upon pharmacy education. registering and completing the activity evaluaCredit Designation This program is assigned ACPE Universal Activity tion, your transcript information will be sent to #0797-9999-19-096-L01-P. This program is des- the NABP CPE Monitor Service. ignated for up to 1.25 contact hours (.125 CEUs) DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) reof continuing pharmacy education credit. quires instructors, planners, managers, and other Type of Activity individuals who are in a position to control the Application content of this activity to disclose any real or apPharmacists have up to 30 days to complete

parent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Faculty disclosures may be found on the CMHC Mobile App. Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose. The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose. DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

www.cardiometabolichealth.org

CME Breakfast Symposium A SATURDAY, OCTOBER 12

6:30 â&#x20AC;&#x201C; 7:45 AM | GREAT LAKES (AB) BALLROOM

The Potassium Dilemma in HF and CKD: Challenges and Advancements in the Management of Hyperkalemia Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term

outcome data to guide in the management of this condition. This symposium will provide clinicians with clinical evidence on the new potassium-binding agents for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward optimizing guideline-directed medical therapy for hyperkalemic patients with HF and CKD. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

George L. Bakris, MD (Chair)

Biff F. Palmer, MD

Peter A. McCullough, MD, MPH

Matthew R. Weir, MD

Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Professor of Medicine Vice Chief of Internal Medicine Baylor University Medical Center Dallas, TX

36 www.cardiometabolichealth.org

Professor of Internal Medicine University of Texas Southwestern Medical Center Dallas, TX

Professor and Director Division of Nephrology University of Maryland School of Medicine Baltimore, MD

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Identify patients at risk for hyperkalemia based on the presence of several modifiable risk factors • Evaluate the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies based on evidence-based guideline recommendations for HF management and appropriate monitoring for renal function and hyperkalemia • Interpret the efficacy and safety of current and new treatment options for hyperkalemia • Develop appropriate treatment regimens for hyperkalemia in patients with HF and CKD based on the efficacy, safety, and mechanisms of action of current and new therapies

6:30 – 6:35 am

EDUCATIONAL GRANT SUPPORT

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CREDIT DESIGNATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. PHARMACIST ACCREDITATION STATEMENT Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education. This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19900-L01-P Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT

Overview George L. Bakris, MD (Chair)

6:35 – 6:50 am Hyperkalemia in HF and CKD: Current Challenges Peter A. McCullough, MD, MPH 6:50 – 7:15 am

Assessing the Evidence: New Treatments for Hyperkalemia Biff F. Palmer, MD

7:15 – 7:35 am

Patient Case and Panel Discussion Presenter: Matthew R. Weir, MD Panel: All faculty

7:35 – 7:45 am

Conclusions and Audience Q&A All faculty

This satellite symposium is multi-supported by educational grants from AstraZeneca and Relypsa, Inc.

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity. This is a Level II activity. ABIM MOC CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID 14530. Upon registering and completing the activity evaluation, your certificate will be made available immediately. For Pharmacists: Please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14530. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other

individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Faculty disclosures may be found on the CMHC Mobile App. The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose. DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

www.cardiometabolichealth.org

CME General Session SATURDAY, OCTOBER 12

8:30 â&#x20AC;&#x201C; 9:00 AM | GRAND HORIZON (ABC) BALLROOM

Treatment of High-Risk Patients with CVD and Elevated TGs: REDUCE-IT and Beyond Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Atherosclerotic vascular disease (ASCVD) is the leading cause of death in the United States. Lowering LDL cholesterol (LDL-C) remains central in the prevention and treatment of ASCVD, however, residual risk is present even after the optimization of LDL-C levels. Recent results with icosapent ethyl, as demonstrated by the REDUCE-IT trial, have shown that this agent can significantly reduce atherosclerotic events in high-risk hypertriglyceridemic patients with clinical ASCVD or type 2 diabetes and

additional markers of increased risk. This session will review the role of elevated triglycerides on residual CVD risk, as well as the latest outcomes trials with emerging therapies that help address it and their clinical practice implications. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Christie M. Ballantyne, MD (Chair)

Deepak L. Bhatt, MD, MPH

Professor of Medicine Harvard Medical School Executive Director Interventional Cardiovascular Programs Brigham and Womenâ&#x20AC;&#x2122;s Hospital Heart and Vascular Center Boston, MA

38 www.cardiometabolichealth.org

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Recognize the importance of addressing residual CVD risk, including the role of elevated TG levels in atherosclerosis, based on the evidence and current guidelines • Interpret the recent clinical evidence that addresses residual ASCVD risk in high-risk patients despite statincontrolled LDL-C

8:30 – 8:35 am

Overview Christie M. Ballantyne, MD (Chair)

8:35 – 8:55 am

Addressing Residual CVD Risk Deepak L. Bhatt, MD, MPH

8:55 – 9:00 am

Audience Q&A Christie M. Ballantyne, MD (Chair)

EDUCATIONAL GRANT SUPPORT

This general session is supported by an educational grant from Amarin Pharma, Inc.

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CREDIT DESIGNATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. PHARMACIST ACCREDITATION STATEMENT Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (.05 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19901-L01-P Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activity. This is a Level II activity. ABIM MOC CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID 14531. Upon registering and completing the activity evaluation, your certificate will be made available immediately. For Pharmacists: Please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14531. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other

www.cardiometabolichealth.org

CME Lunch Symposium A SATURDAY, OCTOBER 12

12:00 â&#x20AC;&#x201C; 1:15 PM | GREAT LAKES (AB) BALLROOM

Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complex pathophysiology. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements

in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life. To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This live symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Mariell Jessup, MD (Chair)

Javed Butler, MD, MPH, MBA

Alanna A. Morris MD, MSc, FHFSA, FACC

Ileana L. PiĂąa, MD, MPH, FAHA, FACC

Chief Science and Medical Officer American Heart Association Dallas, TX

Assistant Professor of Medicine, Division of Cardiology Emory University Clinical Cardiovascular Research Institute Atlanta, GA

40 www.cardiometabolichealth.org

Professor and Chairman, Department of Medicine University of Mississippi Jackson, MS

Clinical Prof of Medicine, Central Michigan University Director CVD Research and Academic Affairs Regional and National Director of Heart Failure Detroit Medical Center Detroit, MI

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Identify HFpEF based on current and emerging diagnostic approaches • Develop individualized treatment regimens for HFpEF patients with comorbidities based on current guidelines and evidence • Interpret the efficacy and safety of emerging treatment options and therapeutic strategies in HFpEF based on the latest clinical trial evidence • List approaches and resources aimed to improve hospital readmission rates for patients with HFpEF

12:00 – 12:10 pm Overview Mariell Jessup, MD, FAHA (Chair) 12:10 – 12:20 pm Case Study Mariell Jessup, MD, FAHA (Chair) 12:20 – 12:35 pm Diagnosis of HFpEF Ileana L. Piña, MD, MPH 12:35 – 12:55 pm Treating HFpEF: The Current State of Pharmacotherapies Javed Butler, MD, MPH, MBA 12:55 – 1:05 pm Decreasing hospital readmission rates for HFpEF patients Alanna A. Morris MD, MSc, FHFSA, FACC 1:05 – 1:15 pm

EDUCATIONAL GRANT SUPPORT

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CREDIT DESIGNATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. PHARMACIST ACCREDITATION STATEMENT Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education. This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19715-L01-P Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT

Conclusions and Audience Q&A All faculty

This satellite symposium is multi-supported by educational grants from Abbott and Novartis Pharmaceuticals Corporation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID 14290. Upon registering and completing the activity evaluation, your certificate will be made available immediately. For Pharmacists: Please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14290. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other

www.cardiometabolichealth.org

CME Lunch Symposium B SATURDAY, OCTOBER 12

12:00 – 1:15 PM | GREAT LAKES (EF) BALLROOM

Advances in Iron Repletion Therapy: Addressing the Burden of Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Iron deficiency (ID) affects up to one-third of the world’s population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients. In this symposium, experts will provide participants with

data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. HF treatment guidelines that emphasize ID recognition and treatment will also be overviewed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Peter A. McCullough, MD, MPH (Chair)

Biykem Bozkurt, MD, PhD, FACC, FAHA

Andy Y. Lee, MD

Gurusher S. Panjrath, MD, FACC, FAHA

Professor of Medicine Vice Chief of Internal Medicine Baylor University Medical Center Dallas, TX

Fellow, Advanced Heart Failure and Transplant University of Washington Seattle, WA

42 www.cardiometabolichealth.org

Director, Heart Failure and Mechanical Circulatory Support Program Associate Professor of Medicine George Washington University School of Medicine Washington, DC

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Define the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life • Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID • Summarize the evidence from the latest clinical trials of iron repletion in HF patients with ID, as well as the updated ACC/AHA/HFSA guidelines for the management of iron deficiency in patients with HF • Develop individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the latest evidence and current guideline recommendations

12:00 – 12:05 pm Overview Peter A. McCullough, MD, MPH (Chair)

EDUCATIONAL GRANT SUPPORT

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CREDIT DESIGNATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. PHARMACIST ACCREDITATION STATEMENT Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education. This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19903-L01-P Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT

12:05 – 12:20 pm Iron Deficiency in HF Gurusher S. Panjrath, MD, FACC, FAHA 12:20 – 12:45 pm Iron Repletion in HF: Evidence from Recent and Ongoing Clinical Trials Biykem Bozkurt, MD, PhD, FACC, FAHA 12:45 – 1:05 pm

Expert Roundtable: Clinical Case Presentation Presenter: Andy Y. Lee, MD Panel: All faculty

1:10 – 1:15 pm

Conclusions and Audience Q&A Peter A. McCullough, MD, MPH (Chair)

This satellite symposium is supported by an educational grant from American Regent.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID 14683. Upon registering and completing the activity evaluation, your certificate will be made available immediately. For Pharmacists: Please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14683. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other

www.cardiometabolichealth.org

CME Dinner Symposium SATURDAY, OCTOBER 12

7:20 â&#x20AC;&#x201C; 8:35 PM | GREAT LAKES (AB) BALLROOM

Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). During this live symposium, faculty will overview the management of hypercholesterolemia to reduce the risk of adverse atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with statin and non-statin therapies according to the updated guidelines. In addition, the symposium will summarize the evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources

to address this issue will also be reviewed. During the activity, case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing for enhanced competence in the individualization of therapy for patients at-risk for ASCVD. TARGET AUDIENCE This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Christie M. Ballantyne, MD (Chair)

Leslie Cho, MD

Professor of Medicine Section Head, Preventive Cardiology and Rehabilitation Cleveland Clinic Cleveland, OH

44 www.cardiometabolichealth.org

LEARNING OBJECTIVES

AGENDA

After completing this activity, the participant should be better able to: • Identify patients with elevated LDL-C who are statin intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and diagnostic guidelines • List new and emerging treatment options for ASCVD prevention or management in high-risk patients with hypercholesterolemia • Develop individualized treatment regimens for prevention of adverse cardiovascular events in highrisk patients with elevated LDL-C and comorbidities based on the current ACC/AHA guidelines and evidence about the safety and efficacy of non-statin therapies • Employ strategies and resources designed to improve patients’ access to new treatment options for hypercholesterolemia that may minimize risk of adverse cardiovascular events

7:20 – 7:30 pm Overview and LDL-C Treatment Intensification Christie M. Ballantyne, MD (Chair) 7:30 – 7:45 pm Audience Interaction with DecisionSim Patient Case Leslie Cho, MD 7:45 – 7:50 pm Identifying Patients at Risk for Residual Risk Despite Statin Therapy Leslie Cho, MD 7:50 – 8:10 pm Non-Statin Therapies for LDL-C Christie M. Ballantyne, MD (Chair) 8:10 – 8:20 pm DecisionSim Discussion All faculty 8:20 – 8:30 pm Challenges in PCSK9 Inhibitor Access Christie M. Ballantyne, MD (Chair) 8:30 – 8:35 pm Conclusions and Audience Q&A All faculty

EDUCATIONAL GRANT SUPPORT JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CREDIT DESIGNATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. PHARMACIST ACCREDITATION STATEMENT Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education. This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19904-L01-P Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. DIETICIAN ACCREDITATION STATEMENT

This satellite symposium is multi-supported by educational grants from Sanofi and Esperion. Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity. This is a Level II activity. ABIM MOC CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/ Evaluation by Course” and search by course ID 14635. Upon registering and completing the activity evaluation, your certificate will be made available immediately. For Pharmacists: Please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14635. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other

www.cardiometabolichealth.org

2019

SCIENTIFIC POSTER SESSIONS

P001. Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Events: Translating Basic Science Into Clinical Benefit. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Pater C, Haziza C, Elamin A, Pouly S, de La Bourdonnaye G, Tran CT, Blanc N, van der Plas A, Heremans A Philip Morris International P002. Non-pharmacological Management of Atrial Fibrillation- Complications of Left Atrial Appendage Closure in Diabetic v Non-Diabetic Patients. Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Khomutova A Oakland University William Beaumount School of Medicine, Rochester, MI

P003. Omental Adipose Removal Decreases High Blood Pressure in Hypertensive Patients Independent of Body Mass Index. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Jiang L1, Sun W1, Zhang M2, Wang Y1, Tian Y2, Li P2, Lu Y2, Xu T1, Qiu M3, Yang Y3, Jia X3, Zhou B2, Kong X1 1. Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; 2. Department of Pediatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; 3. Department of Gynecological Tumor, Nanjing Maternity and Child Health Hospital, Nanjing, Jiangsu, China. P004. Implementation of Rotational Thromboelastometry in Patients Undergoing Cardiac Surgery. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Rodriguez-Martin I, Sánchez-Mora C, Sánchez-Margalet V Clinical Biochemistry, Virgen Macarena University Hospital, University of Seville, Seville, Spain. 46 www.cardiometabolichealth.org

P005. Do Depressed Persons with Non-Cardiovascular Morbidity Have a Higher Risk of CVD? A Population-Based Cohort Study in Sweden. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Almas A1,2, Moller J1, Iqbal R3, Lundin A1, Forsell Y1 1. Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; 2. Department of Medicine, Aga Khan University, Karachi, Pakistan; 3. Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan P006. Role of Triglyceride Monitoring in Patients with Familial Chylomicronemia Syndrome. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Priedane E1, Juniat S1, Philips GA2, Hurst S2, Soran H3, Davidson M4, Rosenson RS5 1. Huron Consulting Group, Chicago, IL; 2. Akcea Therapeutics, Boston, MA; 3. Central Manchester University Hospital NHS Foundation Trust, Manchester, UK; 4. Department of Medicine, University of Chicago, Chicago, IL; 5. School of Medicine at Mount Sinai, New York, NY. P007. STEMIs with Elder Age May Fare Similar to Young age –An Unexpected Result Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Iqbal SR1, Almas A2, Khan AH3 1. MBBS, Resident level III, Adult Cardiology, Department of Medicine Aga Khan University Hospital, Karachi, Pakistan; 2. MBBS, FCPS (Internal Medicine), FACC, Associate Professor, Cardiology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan; 3. MBBS, FCPS (Medicine and Cardiology) Professor, Cardiology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.

P008. Coronary Lesions in Young South Asians -A High Risk Population Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Iqbal SR1, Almas A2, Khan AH3 1. MBBS, Resident level III, Adult Cardiology, Department of Medicine Aga Khan University Hospital, Karachi, Pakistan; 2. MBBS, FCPS (Internal Medicine), FACC, Associate Professor, Cardiology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan; 3. MBBS, FCPS (Medicine and Cardiology) Professor, Cardiology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan. P009. IDegLira Improves Glycemic Control in People with Type 2 Diabetes Uncontrolled on Basal Insulin Without Deterioration Despite Discontinuing Pre-trial Sulfonylurea Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Salvesen-Sykes K1, Janez A2, Silver R3, Vilsbøll T4, Grøn R5, Halladin N5, Őrsy P5, Harris S6 1. Novo Nordisk Inc., Plainsboro, NJ; 2. Ljubljana University Medical Centre, Ljubljana, Slovenia; 3. Southern New Hampshire Medical Center, Nashua, NH; 4. Steno Diabetes Center, University of Copenhagen, Copenhagen, Denmark; 5. Novo Nordisk A/S, Søborg, Denmark; 6. Western University, London, ON, Canada. P010. Weight of Evidence of Long-Term Effects of Heavy Metals on the Cardiovascular System at a Population Level Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Saadeh RA1, Klaunig J2, Piatt J2, YousefAgha A2 1. Jordan University of Science and Technology, Irbid, Jordan; 2. School of Public Health, Indiana University, Bloomington, IN.

P013. Soluble ST2 is Directly Correlated with HbA1c in Individuals With an Average Glycaemia In the Normal/Prediabetes Range Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Hasan A1, Al Dahi W2 1. Dasman Diabetes Institute, Dasman, Kuwait; 2. Ministry of Health, Kuwait City, Kuwait P014. Effectiveness and Safety of Apixaban, Dabigatran and Rivaroxaban versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation: ARISTOPHANES Subgroup Analysis Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Deitelzweig S1, Keshishian A2,3, Kang A4, Dhamane A4, Luo X5, Li X4, Balachander N4, Rosenblatt L4, Mardekian J6, Pan X4, Di Fusco M6, Garcia AB4,7, Yuce H3, Lip GYH8 1. Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, LA, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; 2. STATinMED Research, Ann Arbor, MI; 3. New York City College of Technology, City University of New York, New York, NY; 4. Bristol-Myers Squibb Company, Lawrenceville, NJ; 5. Pfizer, Inc., Groton, CT; 6. Pfizer, Inc., New York, NY; 7. University of North Carolina, Chapel Hill, NC; 8. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

P011. Relationship of Vitamin D Deficiency with Glycemic Control in Type 2 Diabetes Mellitus Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Saadeh NA, Saadeh RA, Oweis AO, Alghamri S Jordan University of Science and Technology, Irbid, Jordan P012. Effect of Patiromer in Patients 75 Years or Older with Diabetic Kidney Disease and Hyperkalemia Receiving a RAAS Inhibitor Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Bakris GL1, Woods SD2, Alvarez PJ2, Fogli J2, Arthur S2, Mayo MR2, Kumar R3 1. University of Chicago Medical Center, Chicago, IL; 2. Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA; 3. Midwest Geriatrics, Burr Ridge, IL.

www.cardiometabolichealth.org

2019 SCIENTIFIC POSTER SESSIONS

P016. Relationship Between Biochemical Parameters, Oxidative Stress Markers and Glycemic Control in Type II Diabetes Mellitus Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Fagbohun OF1, Odewole TO2, Emma-Okon BO3, Agboola FK2, Kolawole BA4, Onakpoya OH5 1. Department of Biomedical Engineering, First Technical University, Ibadan, Oyo State, Nigeria; 2. Department of Biochemistry, Obafemi Awolowo University (OAU), Ile-Ife, Osun State, Nigeria; 3. Department of Medical Biochemistry, Obafemi Awolowo University (OAU), Osun State, Nigeria; 4. Department of Medicine, Obafemi Awolowo University (OAU), Ile-Ife, Osun State, Nigeria; 5. Department of Surgery (Ophthalmology Unit), Obafemi Awolowo University (OAU), Ile-Ife, Osun State, Nigeria. P017. Endothelin-1 Gene Polymorphisms in Severe Pulmonary Hypertension Associated with Rheumatic Mitral Stenosis Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Mehra P, Mehta V, Yusuf J, Mukhopadhyay S, Tyagi S G. B. Pant Institute of Postgraduate Medical Education & Research, New Delhi, India P018. Correlation of IL-6, IL-10, IL-18 and TNF-α Levels with Severity of Rheumatic Mitral Stenosis and Secondary Pulmonary Hypertension Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Mehta V, Mehra P, Tripathi G, Yusuf J, Mahajan B, Tyagi S G. B. Pant Institute of Postgraduate Medical Education & Research, New Delhi, India P019. Can Activity Monitoring and Connected Health Increase Physical Activity in Patients with Obesity? A Pilot Study Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM Katayama M1, Paul F1, Scales R1, Buras M1, Lim E1, Bersoux S1, Chaliki H2, Cataldo D3, Fernandes RI2 1. Mayo Clinic, Scottsdale, AZ; 2. Mayo Clinic, Phoenix, AZ; 3. Arizona State University, Phoenix, AZ P020. A Mechanistic Model to Study the Effects of Cardiometabolic Risk Factors in the Progression of Chronic Kidney Disease and Renal Anemia and its Feedback on Heart Health. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Sarkar J, Ramaswamy R Holmusk, Singapore P021. Association Between Post Myocardial Infarction Depression And Poor Cardiovascular Outcomes In African Americans. Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM Abe T1, Orimoloye O2, Olanipekun T1, Ajose T1, Awak A1 1. Morehouse School of Medicine, Atlanta, GA; 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

48 www.cardiometabolichealth.org